Observation on clinical effect of Huoxue-Jiangtang decoction formula granules in treating prediabetes: a randomized prospective placebo-controlled double-blind trial protocol

Peng-Xiang Zhang¹, Lin Zeng¹, Lu Meng¹, Hui-Lin Li², Heng-Xia Zhao³ and De-Liang Liu³*

Abstract

Background: Prediabetes is a hypermetabolic syndrome with blood sugar levels falling between the normal and diabetes. People with prediabetes have a significantly increased chances of developing diabetes, cardiovascular and cerebrovascular diseases, tumors, dementia, and other diseases in the future when compared to the healthy population. However, prediabetes is mainly treated based on lifestyle intervention, currently without targeted drug treatment plan. Traditional Chinese medicine (TCM), which has a longstanding experience, has been shown in clinical studies to be effective for the treatment of diabetes and its related complications. Furthermore, different dosage forms such as decoction and granule have developed gradually in clinical application. Preliminary studies have found that Huoxue-Jangtang Decoction (HJD), with good hypoglycemic and lipid-regulating effects, is potentially one of the complementary and alternative treatments for prediabetes. Therefore, this project intends to perform a prospective clinical study to observe the clinical effectiveness of HJD on prediabetes and the consistency of the efficacy of formula granules and the elixation.

Methods: This is a prospective, randomized, double-blind, and placebo-controlled clinical trial. A total of 183 participants are randomly assigned to HJD Formula Granules plus lifestyle intervention, HJD Elixation plus lifestyle intervention, and placebo plus lifestyle intervention. All subjects undergo 1 day of screening before participating in the study, followed by 84 days of drug intervention and observation. During and after treatment, the main outcome measures include fasting blood glucose and 2-hour postprandial blood glucose.

Discussion: This research attempts to verify the clinical efficacy and possible mechanism of HJD in the treatment of prediabetes, and prove the consistency of HJD Formula Granules with HJD Elixation. This study also aims to provide a treatment that is both effective and safe for prediabetic patients.

Trial registration: ClinicalTrials.gov Identifier: ChiCTR2200060813, Registered 12 June 2022.

*Correspondence: ldl2580@gzucm.edu.cn

¹ Endocrinology Department of Shenzhen Traditional Chinese Medicine Hospital, No. 1 Fuhua Road, Shenzhen 518033, Guangdong Province, People’s Republic of China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Background**
Prediabetes, considered to be an important clinical stage of diabetes, is a hypermetabolic syndrome with blood sugar levels falling between the normal and diabetes. In the past 40 years, the lifestyle and diet structure of Chinese people have undergone great changes due to a rapidly expanding economy. A lack of exercise and high-calorie diet have significantly increased the proportion of prediabetic and diabetic patients in the Chinese population. The epidemiological statistics in China in 2017 show that 35.2% of the population have pre-diabetes, and 11.2% of the population have diabetes. However, only 4.0% of them have been clearly diagnosed just 49.2% of which have received adequate treatment [1, 2].

When the prediabetic patients do not receive timely diagnosis and treatment, about 5–10% of them will rapidly progress to the stage of diabetes, and the rest will gradually develop diabetes over the next 5 years. In the meantime, the incidence and severity of diseases such as coronary artery disease, heart failure, hypertension and retinopathy in patients with prediabetes are aggravated with more obvious blood glucose fluctuation, thus seriously affecting their quality of life [3–6]. As a result, timely diagnosis and intervention for diabetics can postpone the progression of prediabetes to diabetes and lower the risk of related complications, which is critical for both society and patients.

Fat, a strong temptation for human beings, provides necessary calories for normal physiological activities as one of the important food types. In a meta-analysis of dietary behavior, it is found that Chinese patients with type 2 diabetes generally preferred fat, oil, sweets and meat [7]. Long-term high-fat food intake can reduce an individual's sensitivity to fat, leading to excessive fat intake, weight gain and insulin resistance [8]. Several studies have also discovered that people who consume a high-fat diet are at a markedly increased risk of experiencing prediabetes [9–12]. For this reason, the American Diabetes Association (ADA) recommends that diabetes and prediabetes patients should adjust their lifestyle and choose whole grains and fiber over high-fat, high-calorie and high-sweetness food to reduce the risks associated with diet [13].

The Diabetes Prevention Program has shown that lifestyle intervention can decrease the occurrence of prediabetes conversion by 58% [14]. In addition, lifestyle interventions require no additional financial costs or time requirements, so patients can do corresponding exercise in their free time, which remains the main measure and first choice for the prevention and treatment of prediabetes [15–17]. However, it's not easy for some people to change a long-standing diet or lifestyle, and the lack of a consistently effective lifestyle intervention is also less effective in prediabetes. Although clinical researches have found that metformin, acarbose, orlistat and other drugs can prevent prediabetes from developing into diabetes by reducing body weight, improving glucose metabolism and other mechanisms, etc., there is still no consensus [18–21].

Traditional Chinese medicine (TCM) has been used to treat a wide range of diseases in China for thousands of years. In the process of application, granules, powder and other new formulations have been developed, however, formula granules and elixation are the two most widely used dosage forms. Previous research has found that TCM therapies can noticeably and securely improve the symptoms and clinical indicators of diabetes and prediabetes patients, so it appears to be a potential complementary therapy for prediabetes [22, 23].

In a meta-analysis of 26 randomized controlled trials, TCM treatment delayed the development of impaired glucose tolerance to diabetes and increased the likelihood of normalizing blood glucose in diabetics compared to the control groups. Compared with lifestyle intervention alone or drug therapy alone, TCM therapy had a more significant effect on improving the symptoms and indicators of prediabetes, diabetes and related complications [24].

Huoxue-Jiangtang Decoction (HJD) is the precompounded prescription order of the Endocrinology Department of Shenzhen Traditional Chinese Medicine Hospital (Shenzhen TCM Hospital). Our earlier studies have shown that HJD has the effects of lowering glucose and controlling lipid, improving insulin resistance and reducing oxidative stress reaction, etc. It has been clinically applied to the treatment of T2DM, diabetic nephropathy, diabetic peripheral vascular disease and other diseases, with good therapeutic effect and safety [25–27].

However, research on the efficacy and clinical adverse reactions of HJD in prediabetic patients is still lacking. In addition, while the decoction is effective, the preparation process is tedious and time-consuming. Granules can be taken after mixed with warm boiled water, which can bring great convenience to patients, but there still lack persuasive evidence of efficacy consistency between the two dosage forms. For this reason, we designed this study protocol to evaluate the effectiveness and tolerability.
of HJD in the prevention and treatment of prediabetes. In addition, it is also aimed to verify the consistency between the Elixation of Huoxue-Jiangtang Decoction (HJD Elixation) and the Formula Granules of Huoxue-Jiangtang Decoction (HJD Formula Granules).

Methods/design

Design and setting

This study is a prospective, randomized, double-blind, placebo-controlled trial that has been registered with the China clinical trials registry (registration number: ChiCTR2200060813). All the documents including study protocol, informed consent, and Case Report Forms (CRF) meet the requirement of the Helsinki declaration, and have been reviewed by academic committee and ethics committee of Shenzhen TCM Hospital. This protocol was compiled in line with the SPIRIT 2013 (Table 1).

Participants

Sample size

Sample size is calculated by PASS 15.0 software, with the significance level of 0.05. A total of 189 cases (63 cases in each group) are required to detect inter-group differences in 2.6 mmol/L postprandial 2h glucose, with a statistical power of 90%. The sample size calculation assumes a standard deviation of 2.0 mmol/L and a shedding rate of 20%.

Recruitment

Subjects will be recruited from the inpatients or outpatients in the Endocrinology Department of Shenzhen TCM Hospital as well as local communities through recruitment advertisements or online promotion. The applicants and main members of the department have been well trained, with rich experience in clinical and experimental research. The Endocrinology Department of Shenzhen TCM Hospital has undertaken multi-stage clinical and basic research projects, and advanced experimental equipment as well as abundant outpatients and inpatients, which jointly ensure the source of patients, technical force and research conditions required by this project. Recruitment was carried out on June 1, 2022, and is supposed to be completed on January 31, 2024.

Patient screening

Prior to the trial, potential subjects will undergo screening at Shenzhen TCM Hospital in accordance with the criteria to determine whether they are eligible for the study. At first, doctors will introduce the study to him/her in as much detail as possible, and carefully answer the doubts of subjects and their families. It is critical that the subjects comprehend the purpose, procedure and duration of the study, as well as the benefits, risks and discomfort that may appear in the course of the research (as shown in Fig. 1).

Inclusion criteria

(1). Meet the diagnosis of “prediabetes”, namely, the criteria of “impaired fasting glucose” and “impaired glucose tolerance” in the classification of glucose metabolism state proposed by WHO in 1999 [28]. Which means that fasting glucose $\geq 6.1 \text{ mmol/L}$, $< 7.0 \text{ mmol/L}$ and/or OGTT 2-hour glucose $\geq 7.8 \text{ mmol/L}$, $< 11.1 \text{ mmol/L}$.
(2). $\geq 18$ years old and $< 70$ years old.
(3). HBA1c $\leq 6.5\%$.
(4). Patients who have not participated in any interventional clinical study or clinical trial in the past 3 months.
(5). Patients who are able and willing to sign written informed consent and complete the study.

Exclusion criteria

(1). Diabetics with clear diagnosis.
(2). Women during pregnancy and lactation.
(3). Patients with chronic kidney disease (eGFR$< 60 \text{ mL/min/1.73m}^2$ and/or serum creatinine $> 133 \mu\text{mol/L}$), severe liver dysfunction (any liver enzyme $> 3$ upper limit of normal, abnormal coagulation function or bilirubin), severe cardiac dysfunction (such as NYHA III or above heart failure, myocardial infarction, and arrhythmia), acute stage of cerebrovascular disease, or malignant diseases that are being treated or have not been fully alleviated or cured.
(4). Patients using high-dose probiotics (daily intake $> 10^8 \text{ cFU}$) in the past 6 months.
(5). Patients using glucocorticoids, cytokines that can stimulate the body’s immune system, methotrexate and other immunosuppressants in the past 6 months.
(6). Patients systematically using antibiotics in the past 6 months.
(7). Patients using local antibiotics in oral cavity within 7 days (such as toothpaste and mouthwash containing antibiotics).
(8). Patients with an irregular diet in the past 3 months (the same meal time interval of more than 2 hours).
(9). Patients with untreated oral abscess.
(10). Patients with oral fungal infection.
(11). Patients with oral precancerous lesions or oral cancers.
### Table 1  A standard protocol items: recommendation for interventions for trials (SPIRIT)

| Items                               | Run-in period | Intervention period | Follow-up period |
|-------------------------------------|---------------|---------------------|------------------|
|                                     | -1st week     | 1st week            | 12th week        | 24th week       |
| **patients**                        |               |                     |                  |
| Informed Consent                    |               | X                   |                  |
| In/exclusion criteria               |               | X                   |                  |
| Randomization and allocation        |               | X                   |                  |
| **Intervention**                    |               |                     |                  |
| HJD Formula Granules group          |               |                     |                  |
| HJD Elixation group                 |               |                     |                  |
| Placebo control group               |               |                     |                  |
| **Outcomes**                        |               |                     |                  |
| HBA1c, FBG, 2hPG                    |               | X                   | X                | X               |
| Cytokines (CRP, PCT, IL-6 and Adiponectin) | X   | X                   | X                |
| Oral LA threshold                   |               | X                   | X                |
| Dietary preference                  |               | X                   | X                |
| Saliva and intestinal microbiota    |               | X                   | X                |
| Saliva and intestinal metabolome    |               | X                   | X                |
| **Safety**                          |               |                     |                  |
| Adverse events                      |               | X                   | X                | X               |
| Drop-out and withdrawals            |               | X                   | X                | X               |
(12). Patients with chronic periodontal diseases requiring long-term treatment.

(13). Patients allergic to any of the ingredients in linoleic solution.

(14). Persons not suitable for this project according to the researcher because of mental, psychological factors, etc.

Randomization

Random number tables are provided by statistical professionals and generated by DAS software. The preparation of drug documentation and emergency correspondence is completed by personnel not involved in the clinical trial. Once subjects are recruited in the study, they will be randomly allocated into three groups at a 1:1:1 ratio, namely HJD Formula Granules group \((n=63)\), HJD Elixation group \((n=63)\) and placebo group \((n=63)\). During the trial, drugs will be distributed based on the time sequence of patients’ inclusion for observation and drug number. Drugs shall not be selected, and the drug number will remain unchanged throughout the trial.

Blinding

This is a double-blind trial in which all the staff, investigators, sponsors and statisticians are blinded. The test drug and placebo are accompanied by an emergency letter with corresponding number, which are kept by the principal investigator. In the serious adverse events, or in need for emergency treatment, the investigator will report to the supervisor and the principal investigator and decide whether to open the emergency letter. The over 20% of opening rate in blind records leakage or emergency letter indicates test failure. After case collection is completed, the database is established and the data is locked, unblinding measures will be performed.

Withdrawal criteria and management

Medication will be adjusted or terminated if any of the following conditions occur.

1. Severe adverse events related to abnormal blood glucose, such as diabetic ketosis, and hyperosmolar hyperglycemic state.

2. The occurrence of other serious cardiac, cerebral and renal vascular diseases during the test.

3. Severe gastrointestinal reactions.

4. The subjects deviate significantly from test requirements or want to withdraw from the study.

5. Investigators conclude that the subjects are no longer fit for participating in the study.

Intervention

The main intervention measures include oral HJD Formula Granules, HJD Elixation or placebo in addition to daily lifestyle intervention. The individual personnel will package and label the investigational drug and placebo in accordance with random-number tables and drug blinds. All drugs are concealed in uniform packages with the same label and a 28-day supply. At each visit, the researchers will ask the patient about their medication and count the remaining dose to improve their compliance. Besides, any drug with a clear hypoglycemic effect figure 1.png
shall not be used. Previous studies have proved that HJD has the effects of regulating glucose and lipid metabolism, improving inflammation and oxidative stress state, and improving insulin resistance, with good therapeutic effects on type 2 diabetes, metabolic syndrome, and diabetic nephropathy, etc. [25, 29, 30] The dosage of HJD Formula Granules and HJD Elixation is determined by the long-term clinical application experience of our hospital.

The subjects will also be instructed according to the prediabetic lifestyle intervention program contained in Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 edition) [31]. Generally speaking, it mainly includes but is not limited to diet control, exercise and health education, etc. [31]

**Experimental group**

After randomization, 63 subjects will receive HJD Formula Granules and 63 subjects will receive HJD Elixation. The two groups will both take the drug by a single dose of 20 g, 3 times/day, before or after meals, coordinating with lifestyle interventions and continued for 12 weeks.

HJD Formula Granules are provided by Yifang Pharmaceutical Industry. Specifically, the single herb will first be decocted and concentrated to prepare the single herb granules, and then mixed different granules to form the formula granules of HJD. HJD Elixation is prepared by the Pharmacy Department of Shenzhen TCM Hospital. Specifically, the decoction pieces of various herbs are first mixed according to the dosage of HJD, and then form the granules after decocting, concentrating and drying. Whole ingredients of HJD Formula Granules and Elixion are as shown in the Table 2.

**Control group**

The placebo control group (n = 63) will take the placebo by a single dose of 20 g, 3 times/day, before or after meals, coordinate with lifestyle interventions and continued for 12 weeks. The Chinese herbal medicine placebo contains pharmaceutical excipients, natural pigments, natural flavoring agents, and granules in the same amount as the test drugs. Its appearance, shape and taste are similar to HJD Formula Granules and HJD decoction Elixation, but it does not have efficacy.

**Outcome measurements**

**Sample collection, storage, analysis and destruction**

Researchers should communicate with subjects before sample collection, obtain consent of subjects, and sign informed consent. Subjects are forbidden to eat, drink, brush and floss teeth 12 hours before sample collection.

| **Latin binomial nomenclature.** | **Chinese name** | **dosage** |
|----------------------------------|-----------------|-----------|
| *Rehmannia glutinosa* Libosch. | *Sheng Di Huang* | 30 g      |
| *Ophiopogon japonicus* (L. f) Ker-Gawl. | *Mai Dong* | 20 g      |
| *Pseudostellaria heterophylla* (Miq.) Pax ex Pax et Hoffm. | *Tai Zi Shen* | 30 g      |
| *Rheum officinale* Bail. | *Da Huang* | 6 g       |
| *Dioscorea opposita* Thunb. | *Shan Yao* | 10 g      |
| *Astragalus membranaceus* (Fisch.) Bge. var.mongholicus (Bge.) Hsiao | *Huang Qi* | 30 g      |
| *Carthamus tinctorius* L. | *Hong Hua* | 15 g      |
| *Prunus persica* (L.) Batsch. | *Tao Ren* | 10 g      |

(1). Blood collection: 5 ml blood sample should be collected from the median cubital vein at 8:00 a.m. when participants are fasting for more than 8 hours.

(2). Saliva collection: Samples will be collected at 8:00 a.m. when participants are fasting for more than 8 hours. Non-irritating methods will be employed to collect saliva samples which should flow naturally into 50 ml EP tube instead of expectorating until 10 ml saliva is collected.

(3). Supringlyal plaque samples collection: Researcher should use sterile curettes to scrape the plaque of subjects’ upper and lower anterior teeth, premolars and buccal side of molars, and place the supringlyal plaque samples in 1.5 mL EP tubes.

(4). Intestinal flora collection: Researcher should collect 2-5 g of fresh and naturally discharged stool samples (the middle part of the stool) with fecal DNA collection tube, avoid mixing with urine or other substances, and replace the clean 5 ml centrifuge tube cover and tighten the collection tube again.

Samples should be placed in −80°C refrigerator immediately after collection, and avoid repeated freezing and thawing.

After each sample is analyzed, it will undergo harmless treatment according to the requirements of laboratory waste.

**Observation index and laboratory examination**

During the visit, investigators will arrange the subjects to complete the corresponding examination according to the study progress. Except for physical examination, electrocardiogram and other routine examination, the 3-alternative forced-choice procedure (3-AFC) [32]
will be used to detect the threshold of linoleic acid (LA). Subjects in each group will be also guided to complete a modified questionnaire [33] to determine their dietary preferences during the previous 3 months. Saliva and stool samples collected during the study will be analyzed for metabonomics. Specific methods are as follows:

1. Complete physical examination: Specific examination items include general condition (height, weight, BMI, and abdominal circumference), respiratory, cardiovascular, abdominal, skin, head and neck, lymph nodes, thyroid, musculoskeletal (including spine and limbs) and nervous system examination.

2. Routine biochemical tests: Specific tests include blood routine, urine routine, routine stool test, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), fasting C-peptide, 2-hour postprandial C-peptide, fasting insulin, 2-hour postprandial insulin, hemoglobin A1c (HbA1c), liver function, renal function, and blood lipid. The above tests will be completed by the medical laboratory of Shenzhen TCM Hospital.

3. Oral LA threshold determination: The threshold will be tested by 3-AFC. The solutions used in the test take deionized water as solute, then add 5% edible grade acacia gum and antioxidant 0.01% EDTA, mix thoroughly with blender for 2 minutes, add 5% edible grade liquid paraffin, mix well again, add edible grade LA, and prepare concentration gradients of 0.02, 0.06, 1,1.4, 2, 2.8, 3.8, 5, 6.4, 8, 9.8, 12, 20 mmol/L LA solution respectively. Blank control solution does not contain LA. All solutions are prepared on the same day and then stored at 4°C for later use. Subjects should fast for at least 8 hours before testing.

During the test, the room should be lit red to avoid visual interference, and the subjects wore nose clips to avoid olfactory interference. At the beginning, each concentration of LA is divided into groups, and each group is lined with 3 small containers, one of which contains different concentrations of LA solution, and the other two are blank control solutions. Starting with the lowest concentration group, subjects are asked to attempt the solutions to identify the LA solution in each of the three containers. At the end of each attempt, they should spit out the solution at the end of each attempt and gargle with deionized water. If the subject is identified incorrectly, he/she will be asked to try the next group with a higher concentration of LA solution. If the subject is identified correctly, the test will be repeated another two times with the same concentration of LA solution. If the subject successfully identifies the same concentration of the solution three times consecutively, this concentration will be the subject’s oral LA-threshold (As shown in Fig. 2).

4. Dietary preference assessment: Dietary preferences will be evaluated by the questionnaire of dietary status in the last 3 months. (As shown in Table 3).
(5). Saliva and intestinal microbiota testing: After thawing saliva and stool samples, total DNA is extracted using commercial bacterial community DNA extraction kit. After the DNA quality inspection, PCR amplification, product purification and PCR product quantification, 16-second high-throughput sequencing is performed using HiSeq 2500. Bioinformatics analysis is then conducted: After quality assurance of the raw data, the data are de-chimerized and clustered using USEarch software. Reads are first sorted according to their abundance from large to small, and obtain OUT (Operational Taxonomic Units) by standard clustering with 97% similarity. Each OUT is thought to represent a species. Following that, Reads from each specimen are extracted at random, and the correlating OUT sequence is extracted. Then, using Qiime software to draw the alpha diversity index dilution curve, and select sensible extraction parameters based on the dilution curve. Use Qiime software to analyze the OUT obtained after extraction. First, a Read is extracted from OUT as a representative sequence. Each OUT will be classified by RDP method to compare the representative sequence with 16S database. After classification, the OUT abundance table is generated based on the number of sequences in each OUT, and the successive analysis is conducted on the basis of the table.

(6). Saliva and intestinal metabolite group detection: After thawing, the saliva and stool samples are mixed, centrifuged, mixed with water of DSS internal standard, centrifuged at low temperature and high speed and detected in a nuclear magnetic tube. 1H-NMR free induction decay (FID) signal will be imported into Chenomx NMR suit (Version 8.0, Chenomx, Edmonton, Canada), and then act Fourier transform, phase adjustment, and baseline correction automatically. Dss-d6 peak (0.0 PPM) is adopted as the chemical shift standard for the whole spectrum, and the spectrum peak shape (CSI) is adjusted by inverse convolution operation. The concentration and peak area of DSS-D6 are used as standards based on signal information in the 1H-NMR spectrum (such as chemical shift, peak shape, half-peak width, and coupling splitting score), and the signal of sample spectrum is compared and analyzed one by one in combination with Chenomx’s own database to obtain the metabolites and the corresponding absolute concentration value. Metabolomics data will be processed using R language, and perform principal component analysis.
(PCA) and partial least square analysis (PLS-DA) followed by metabolic pathway analysis.

(7). Electrocardiogram examination: Electrocardiogram (ECG) is required during the stage of screening. After the subject has rested for at least 5 minutes, the 12-lead ECG should be performed and recorded on the CRFs as “normal” or “abnormal”.

Primary outcomes
The primary outcome is to verify the clinical efficacy and possible mechanism of HJD in the treatment of prediabetes, and to prove the consistency of HJD Formula Granules with HJD Elixation.

It specifically includes the change value of HBA1c, FBG, 2hPG prior to and following treatment.

Secondary outcomes
The secondary outcomes are to evaluate the comprehensive effect of HJD Formula Granules and HJD Elixation, specifically including:

1. Oral LA threshold determination.
2. Dietary preference assessment.
3. Changes of body weight and BMI.
4. Time of blood glucose reaching standard.
5. Changes of fasting C-peptide and 2-hour postprandial C-peptide.
6. Changes of cytokines such as CRP, PCT, IL-6 and Adiponectin.

Exploratory outcome measure
The exploratory outcomes are to evaluate the effects of HJD Formula Granules and HJD Elixation on oral and intestinal microflora, blood lipid, liver function, and urine function, specifically including:

1. Detection of Salivary and intestinal microbiota and metabolite group.
2. Blood lipid: TG, TC, LDL-c, HDL-c, Apo-A and Apo-B.
3. Liver function: ALT, AST, GGT, albumin and bilirubin.
4. Urine function: BUN, serum creatinine, eGFR, Uric Acid.

Safety capability evaluation
Safety capability evaluation refers to evaluating the tolerability and safety of HJD Formula Granules and HJD Elixation, specifically including:

1. AEs/SAEs.
2. Vital signs.
3. Laboratory inspection.
4. ECG.

Data management
In order to facilitate the subjects to complete the whole study, they will be reminded at each visit point by phone or text message to come to the hospital for relevant examination. All data generated by subjects during the study shall be recorded in the CRFs in detail and truthfully.

With informed consent, uniformly trained investigators will gather data in compliance with the researchers’ manual and Standard Operating Procedure (SOP) formulated in advance. During this period, independent monitors review the data in real time to ensure the accuracy and completeness. In order to facilitate the later data check, all data modification should leave traces. In the case of paper CRFs, the original data should not be changed when the record is corrected or the errors are filled in. Instead, additional statements should be used. A line should be drawn on the original error and the correct data should be written next to it. If inputting the date on the electronic database, the database system should have the function of leaving traces to record the data before modification, modification reason, modification personnel and date as well as other information.

After the completion of data entry, data verification and cleaning are required. For the data with missing information, logical contradiction, error or uncertainty, the supervisor will deliver it to the researcher in the form of question list, and the researcher should answer the question. After verification, the database data will be revised. Any problems found during data verification and cleaning should be notified to the supervisor in time and the researchers are required to answer them. All kinds of questions and answers should use the question sheet, including the request for data supplement and review, etc. All query tables, and error data contents and modification results shall be recorded in detail and properly preserved.

The data of this research may be published in medical publications, but we will keep the subjects’ information secret as needed by law, and personal information about the subjects will not be revealed unless required by relevant laws.

Statistical analysis
Primary, secondary, exploratory end points and safety assessments will be analyzed when the last patient completes the follow-up or drops out of the study. Analyses of clinical data will be performed by the principal
Continuous variables are used to evaluate the number of cases, mean, standard deviation, median, minimum, and maximum for demographic data and other baseline eigenvalues. Frequency and composition ratio are calculated using count and grade data. Descriptive results involve inferential statistical results (p-values).

For the analyses of laboratory data and clinical efficacy of drugs, chi-square test or Fisher’s exact test are used for counting data, while ANOVA and T test are used for measurement data. The grade data is analyzed by Ridit and CMH. The ratio or percentage of counting data is expressed, and the measurement data is expressed as mean± standard deviation. All statistical tests are conducted by two-sided tests, with P<0.05 indicating statistical significance. Multiple imputation will be used for missing data.

**Adverse events**

Although no serious adverse events have been reported with this formulation in previous studies, subjects may have vomiting, diarrhea and other adverse reactions because of individual difference.

Specifically, adverse reactions include clinical symptoms (such as nausea, fatigue, dizziness, abdominal pain, and itching), signs (such as jaundice, rash, and fever), diseases and abnormal laboratory tests, etc. Adverse events are classified as “mild”, “moderate”, or “severe” based on severity. All adverse reactions and their incidence, duration, severity and treatment measures, ending, and the relationship between drug and its dosage will be detailed and fully documented in the CRFs. When a patient experiences an adverse event and does not show significant remission after treatment, the researcher will inform the chief investigator and the ethics committee. Then modification or termination will be conducted to ensure the safety and interests of the subject.

**Trial monitoring**

The academic committee of Shenzhen TCM Hospital is responsible for reviewing the scientific nature and compliance of the protocol and making recommendations for the continuation or termination of the study. The ethics committee is responsible for reviewing the rationality of the protocol and safeguarding the rights and interests of the subjects. Both members are independent of the sponsors and researchers, and there is no conflict of interest.

**Discussion**

The study’s goal is to investigate the effectiveness and difference of TCM decoction and granule in the management of prediabetes, to clarify whether HJD can adjust fat preferences, and oral and intestinal microbiota of prediabetic patients, and subsequently to slow or prevent the transition from prediabetes to diabetes.

Elixation and granule are the two main dosage forms of TCM treatment, which are widely used in clinic. However, there are few placebo-controlled studies on TCM decoction for prediabetes. After treating prediabetic rats with TCM granules, Wang and colleagues [34] found that TCM granules significantly improved body weight and glucolipid metabolism in rats, and increased insulin sensitivity to an effect similar to that of rosiglitazone. Wei [35] also confirmed in a multi-center trial that TCM granules could restore normal blood glucose in 41.8% of prediabetic patients (27.8% in the control group) after 12 months of intervention. However, the follow-up showed that the granules group had weak lasting effect, and there was no improvement in subjects’ HBA1c levels. Therefore, this study expands the function of TCM elixation in the management of prediabetes, and hopes to significantly improve the symptoms and indicators of prediabetes patients.

Eating habits are closely related to people’s life. People often crave fat because it provides more calories and pleasure [36]. However, high-fat diets also lead to weight gain and decreased sensitivity to fat, which further increases people’s intake of high-fat diets [37, 38]. Poor diet quality has been reported to significantly increase the risk of prediabetes (OR: 1.45, 95% CI: 1.29–1.63) [39], and also affect the changes of oral and intestinal flora [40, 41].

Human saliva contains abundant biological information, and the oral flora can reflect various physiological and pathological changes of the human body. Amr and Kornwipa [42, 43] found that the number of species in oral saliva decreased with the progression of diabetes, and that diabetics exhibited the largest pathogenic microbiome. However, the sample size of their researches was small, the changes of oral microflora in prediabetic patients need to be further explored in a larger sample.

In addition, hyperglycemia will lead to abnormal intestinal flora, further destroy the intestinal barrier, and cause damage to glucose metabolism and immune homeostasis. The study confirmed that after 12 weeks of supervised training, prediabetic patients experienced significant changes in their gut microbiota, as well as remarkable improvements in insulin sensitivity and other metabolic characteristics. After excluding the interference of body weight and visceral fat, correlation analysis confirmed a significant association between the two [44]. What’s more, prediabetes patients had increased multiple butyrate-producing bacteria after inserting the gut microbiota of a healthy person, which could convert fiber into short-chain fatty acids, and then released GLP-1 to
suppress appetite and promote weight loss through gut–brain neural circuit [45].

In previous studies, we found that HJD has a good therapeutic effect on metabolic diseases [25–27, 29, 30], and have improved the preparation process of TCM placebo which had been applied for a patent [46], providing a corresponding clinical basis for this study. Therefore, we designed this study to further evaluate the effect of HJD Elation and Formula Granules in treating prediabetes, the results may also discover the effect of HJD in oral LA threshold, dietary preference, saliva and intestinal microbiota of prediabetes patients, thus to further explain its potential therapy mechanism.

Abbreviations
TCM: Traditional Chinese medicine; HJD: Huoxue-Jingtang Decoction; ADA: American Diabetes Association; CRF: Case Report Forms; 3-AFC: 3-alternative forced-choice procedure; LA: Linoleic acid; FBG: Fasting blood glucose; 2hPG: 2-hour postprandial blood glucose; HbA1c: hemoglobin A1c; FID: Free induction decay; PCA: Principal component analysis; ECG: Electrocardiogram; SOP: Standard operating procedure.

Acknowledgments
Not applicable.

Protocol version
20220323V1.

Authors’ contributions
DLL is responsible for the design and monitoring of this study. PXZ and LZ drafted the manuscript, and they contributed equally to this work. PKZ, LZ, LM is responsible for enrollment, drug distribution, follow-up examination and data collection. LM carried out the statistical analysis and interpretation for the study. HLL and HXZ supervised the feasibility of study program and revised the manuscript’s final version for publication. All authors have perused and approved the manuscript.

Funding
The project is supported by Guangdong Basic and Applied Basic Research Foundation (No. 2021A1515220177). All funders will have no involvement in research design, data gathering, analysis, interpretation, or manual writing.

Availability of data and materials
Following the completion of the present research, the datasets used and/or analyzed will be made accessible to the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
The ethics committee of Shenzhen TCM Hospital has approved the study after reviewing the trial protocol (No. K2022–013). Before being accepted into our study, all participants were given and signed a written consent form.

Consent for publication
Not applicable.

Competing interests
The authors have no conflicts of interest to disclose.

Author details
1 The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, People’s Republic of China. 2 Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, People’s Republic of China. 3 Endocrinology Department of Shenzhen Traditional Chinese Medicine Hospital, No. 1 Fuhua Road, Shenzhen 518033, Guangdong Province, People’s Republic of China.

Received: 25 June 2022   Accepted: 10 October 2022
Published online: 19 October 2022

References
1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317(24):2515–23.
2. Li Y, Teng D, Shu X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020;369:m997.
3. Muhammed A, Zaki MT, Elserafy AS, et al. Correlation between prediabetes and coronary artery disease severity in patients undergoing elective coronary angiography. Egypt Heart J. 2019;71(1):34.
4. Cai X, Liu X, Sun L, et al. Prediabetes and the risk of heart failure: a meta-analysis. Diabetes Obes Metab. 2021;23(8):1746–53.
5. Geva M, Shlomai G, Berkovich A, et al. The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension. Cardiovasc Diabetol. 2019;18(1):53.
6. Jin J, Lu P. Association between prediabetes and retinopathy: a Meta-analysis. Horm Metab Res. 2021;53(12):801–9.
7. Wang B, Jin R, Xu J, et al. Association between dietary factors and type 2 diabetes mellitus in Chinese population: a meta-analysis. J Evid Based Med. 2004;07(03):136–40.
8. Heinzer JM, Costanzo A, Baselier I, et al. Detection thresholds for four different fatty stimuli are associated with increased dietary intake of processed high-caloric food. Appetite. 2018;123:7–13.
9. Cao Y, Chen C, Cui L, et al. A population-based survey for dietary patterns and prediabetes among 7555 Chinese adults in urban and rural areas in Jiangsu Province. Sci Rep. 2020;10(1):10488.
10. Pestoni G, Riedl A, Breuninger TA, et al. Association between dietary patterns and prediabetes, undetected diabetes or clinically diagnosed diabetes: results from the KORA FF4 study. Eur J Nutr. 2021;60(5):2331–41.
11. Shen XM, Huang YQ, Zhang XY, et al. Association between dietary patterns and prediabetes risk in a middle-aged Chinese population. Nutr J. 2020;19(1):71.
12. Hou YC, Feng HC, Tzeng ES, et al. Dietary patterns and the risk of prediabetes in Taiwan: a cross-sectional study. Nutrients. 2020;12(11):3322.
13. Lifestyle Management. Standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46–60.
14. Ford CN, Weber MB, Staimez LR, et al. Dietary changes in a diabetes prevention intervention among people with prediabetes: the diabetes community lifestyle improvement program trial. Acta Diabetol. 2019;56(2):197–209.
15. Chen X, Zhao S, Hsu C, et al. Effects of aerobic training and resistance training in reducing cardiovascular disease risk for patients with prediabetes: a multi-center randomized controlled trial. Prim Care Diabetes. 2021;15(6):1063–70.
16. Ackermann RT, O’Brien MJ. Evidence and challenges for translation and population impact of the diabetes prevention program. Curr Diab Rep. 2020;20(3):9.
17. Fritsche A, Wagner R, Hens M, et al. Different effects of lifestyle intervention in high- and low-risk prediabetes: results of the randomized controlled prediabetes lifestyle intervention study (PLIS). Diabetes. 2021;70(12):2785–95.
18. Warnlow A, Somerset S, Pumpa K, et al. Metformin use in prediabetes: is earlier intervention better? Acta Diabetol. 2020;57(11):1359–66.
19. Dutta D, Jaisani R, Khandelwal D, et al. Role of metformin, sodium-glucose Cotransporter-2 (SGLT2) inhibitors, glucagon-like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and Euglycemia in Diabesity: a real-world experience. Indian J Endocrinol Metab. 2019;23(4):460–7.
20. Gerstein HC, Coleman RL, Scott C, et al. Impact of Acardose on incident diabetes and regression to Normoglycemia in people with coronary heart disease and impaired glucose tolerance: insights from the ACE trial (J. Diabetes Care. 2020;43(9):2242–7.
21. Davidson MB. Metformin should not be used to treat prediabetes. Diab-etes Care. 2020;43(9):1983–7.
22. Karimi-Nazari E, Nadjardzeih A, Masoumi R, et al. Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: a double-blinded, randomized controlled trial. Clin Nutr ESPEN. 2019;34:130–6.
23. Liu BW, Huan Z, Yan-miao M, et al. Clinical research on IGT treated with compound gegen capsules combine with lifestyle in characteristics of TC. China J Tradit Chin Med Pharm. 2018;33(08):5734–6.
24. Tian J, Jin D, Bao Q, et al. Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(8):1801–16.
25. Li M. To explore the mechanism of Huoxue-Jiangtang decoction in treating type 2 diabetes based on intestinal flora homeostasis and insulin resistance. Guangzhou: Guangzhou University of Chinese Medicine; 2020.
26. Liu X, Liu D., Zeng L et al., Mechanism of Huoxue Jiangtang drink in the intervention of diabetic nephropathy based on transcriptome sequenc-ing technology. World Chinese Medicine, 2021;16(14):2120–2128.
27. Deng Y. Clinical study of Huoxue Jiangtang decoction in the treatment of diabetic lower extremity atherosclerotic disease. Guangzhou: Guangzhou University of Chinese Medicine; 2020.
28. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.
29. Liu X, Liu D, Shuai Y, et al. Effects of Huoxue Jiangtang decoction alone or in combination with metformin on renal function and renal cortical mRNA expression in diabetic nephropathy rats. Pharm Biol. 2020;58(1):1125–30.
30. Zhang LQ. Effect of Huoxuejiangtang decoction on metabolic syndrome and Hs-CRP expression. Modern Tradit Chin Med. 2011;31(04):41–2.
31. Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Int J Endocrinol Metab. 2021;41(05):482–548.
32. Chevrot M, Passilly-Degrace P, Ancel D, et al. Obesity interferes with the orosensory detection of long-chain fatty acids in humans. Am J Clin Nutr. 2014;99(5):973–83.
33. Asano M, Hong G, Matsuyama Y, et al. Association of Oral fat Sensitivity with body mass index, taste preference, and eating habits in healthy Japanese young adults. Tohoku J Exp Med. 2016;238(2):93–103.
34. Wang H, Guo L, Shang H, et al. JinqiJiangtang tablets for pre-diabetes: a randomized, double-blind and placebo-controlled clinical trial. Sci Rep. 2017;7(1):11190.
35. Wei Y, Hong Y, Hou P, et al. Effect of sugar-free Qishan granules on glucose and lipid metabolism and insulin resistance in a rat model of prediabetes. J Tradit Chin Med. 2019;39(4):535–41.
36. Drewnowski A. Why do we like fat? J Am Diet Assoc. 1997;97(Suppl):S58–S62.
37. Daoudi H, Plesnik J, Sayed A, et al. Oral fat sensing and CD36 gene polymorphism in Algerian lean and obese teenagers. Nutrients. 2015;7(11):9096–104.
38. Sayed A, Seri O, Plesnik J, et al. CD36 AA genotype is associated with decreased lipid taste perception in young obese, but not lean, children. Int J Obes. 2015;39(6):920–4.
39. He D, Qiao Y, Xiong S, et al. Association between dietary quality and prediabetes based on the diet balance index. Sci Rep. 2020;10(1):3190.
40. Chumpornsuk T, Gruneck L, Gentekaki E, et al. The salivary microbiota of Thai adults with metabolic disorders and association with diet. Arch Oral Biol. 2021;122:105036.
41. Asnicar F, Berry SE, Valdes AM, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021;27(2):321–32.
42. Saeb A, Al-Rubeaan KA, Aldosary K, et al. Relative reduction of biological and phylogenetic diversity of the oral microbiota of diabetes and pre-diabetes patients. Microb Pathog. 2019;128:215–29.
43. Rungrueang K, Yuma S, Tantipoj C, et al. Oral bacterial microbiomes in association with potential prediabetes using different criteria of diagnosis. Int J Environ Res Public Health. 2021;18(4):7436.
44. Liu Y, Wang Y, Ni Y, et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab. 2020;31(1):77–91.